Buyer Disclosure Schedule. CAPITALIZATION Set below are lists of all securities (including outstanding warrants, options, agreements, convertible securities or other commitments to which Aquinox Pharmaceuticals Inc. or Aquinox Pharmaceuticals (USA) Inc. may become obligated to issue any shares of its capital stock or other securities) of Aquinox Pharmaceuticals Inc. and Aquinox Pharmaceuticals (USA) Inc. outstanding as of the Effective Time, and the holders of any interest in such securities. Issued and Outstanding Shares of Aquinox Pharmaceuticals Inc. Shareholders No. New Common Shares No. of Common Exchangeable Shares Held No. of Special Voting Shares Held No. of Series A-1 Exchangeable Shares No. of Series A-2 Exchangeable Shares No. of Non- Voting Preferred Shares Xxxxx X. Main and Xxxxx X. Main as trustees of the Main Family Trust 1,500,000 1,500,000 — — — Xxxxx X. Main 55,000 55,000 — — — Ventures West 8 Limited Partnership — 70,000 9,160,098 5,454,545 3,636,363 — B.C. Advantage Funds (VCC) Ltd. — — 5,485,958 3,667,777 1,818,181 — Xxxxxxx & Xxxxxxx Development Corporation — — 8,181,817 — — — Xxxxx Bros. Investments II, L.P. — — 9,090 — — — 667, L.P. (formerly Xxxxx Biotech Fund I, L.P.) — — 1,218,181 — — — Xxxxx Brothers Life Sciences, L.P. — — 3,213,635 — — — 14159, L.P. — — 104,545 — — — Aquinox Pharmaceuticals (USA) Inc. 1 — — — — 5,200,400 [***] [***] [***] [***] [***] [***] [***] TOTALS 1 5,793,776 33,708,727 9,733,139 5,454,544 5,200,400 Issued and Outstanding Shares of Aquinox Pharmaceuticals (USA) Inc. Series A-1 Special Voting Stock Ventures West 8 Limited Partnership 5,454,545 B.C. Advantage Funds (VCC) Inc. 3,667,777 [***] [***] Total 9,733,139 Series A-1 Preferred Stock Xxxxxxx & Xxxxxxx Development Corporation 4,909,090 Xxxxx Bros Investments II, L.P. 5,454 Xxxxx Brothers Life Sciences, L.P. 1,928,181 14159, L.P. 62,727 667, L.P. (formerly Xxxxx Biotech Fund I, L.P.) 405,468 667, L.P. (formerly Xxxxx Biotech Fund I, L.P.) 325,441 Total 7,636,361 Series A-2 Special Voting Stock Ventures West 8 Limited Partnership 3,636,363 B.C. Advantage Funds (VCC) Inc. 1,818,181 Total 5,454,544 Series A-2 Preferred Stock Xxxxxxx & Xxxxxxx Development Corporation 3,272,727 Xxxxx Bros Investments II, L.P. 3,636 Xxxxx Brothers Life Sciences, L.P. 1,285,454 14159, L.P. 41,818 667, L.P. (formerly Xxxxx Biotech Fund I, L.P.) 487,272 Total 5,090,907 Common Special Voting Stock Xxxxx X. Main and Xxxxx X. Main, as Trustees of the Main Family Trust 1,500,000 Xxxxx X. Main 55,000 Ventures ...
Buyer Disclosure Schedule. FINANCIAL STATEMENTS The Financial Statements are set out on the following pages.
Buyer Disclosure Schedule. Any information disclosed in a Buyer Disclosure Schedule shall be deemed to be disclosed in each other Buyer Disclosure Schedule to the extent that the disclosure made therein is reasonably apparent to be applicable to such other Buyer Disclosure Schedule.
Buyer Disclosure Schedule. Section 1.1(a) Buyer Knowledge Persons
Buyer Disclosure Schedule. The parties agree that the Buyer Disclosure Schedule as attached hereto as Exhibit G shall be the Buyer Disclosure Schedule for the Agreement.
Buyer Disclosure Schedule. Except as set forth in Exhibit 6.6 ("Buyer's Disclosure Schedule") there is no litigation or claim made against Buyer which would be required to be disclosed on Form 10-K if such Form 10-K were required to be filed immediately before the execution and delivery of this Agreement. Seller acknowledges that Seller has received from Parent certain information relating to other pending acquisitions of Parent and its subsidiaries, and the terms of Parent's financing for such acquisitions. Except to the extent that Parent or RIA may be contractually bound or subject to any other legal requirement not to disclose information, all information contained in the Buyer Disclosure Schedule and all other information delivered to Seller by Parent regarding its pending acquisition and financing transactions is true, correct and complete.
Buyer Disclosure Schedule. References to this Agreement shall mean this Agreement as amended or supplemented, together with all Exhibits and Schedules attached or incorporated by reference.
Buyer Disclosure Schedule. Section 1.1(d) Buyer Knowledge Persons OMNIBUS AGREEMENT THIS OMNIBUS AGREEMENT is entered into as of February 13, 2020 (the “Execution Date”), between NextDecade LNG, LLC, a Delaware limited liability company (“Seller”), and Spectra Energy Transmission II, LLC, a Delaware limited liability company (“Buyer”) (Buyer and Seller, collectively, the “Parties” and each, a “Party”). Capitalized terms used herein are defined in Article I or in the Section of this Agreement cross-referenced therein.
Buyer Disclosure Schedule. Article III
Buyer Disclosure Schedule. The term “Buyer Disclosure Schedule” has the meaning set forth in the introduction to Article IV.
